Previous Close | 0.8300 |
Open | 0.8400 |
Bid | 0.8300 x 0 |
Ask | 0.8500 x 0 |
Day's Range | 0.8300 - 0.8700 |
52 Week Range | 0.2500 - 1.8000 |
Volume | 11,536 |
Avg. Volume | 80,668 |
Market Cap | 119.963M |
Beta (5Y Monthly) | -0.21 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0540 |
Earnings Date | Mar 16, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.25 |
RICHMOND HILL, ON / ACCESSWIRE / February 16, 2021 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr.
RICHMOND HILL, ON / ACCESSWIRE / January 28, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company's annual and special meeting of shareholders held on January 28, 2021 (the "Meeting").
RICHMOND HILL, ON / ACCESSWIRE / January 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.